SCHEMBL6045652

SCHEMBL6045652

CCOC(=O)CCCCCn1cnc2c(N)ncnc21

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 2/20 0.72
ADCY5 O95622 5/20 0.66
ADORA2A P29274 5/20 0.61
ADORA1 P30542 3/20 0.56
ADORA2B P29275 1/20 0.56
PI4KA P42356 1/20 0.52
PI4K2B Q8TCG2 1/20 0.52
PI4K2A Q9BTU6 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
FGFR1 P11362 2/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
ADCY1 Q08828 1/20 0.49
HPGD P15428 1/20 0.48
HSP90B1 P14625 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045566 1.00 EP300 (0.72) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL6045654 0.95 EP300 (0.66) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL6045687 0.90 EP300 (0.62) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL6045668 0.87 ADCY5 (0.72) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL28403262 0.84 EP300 (1.00) EP300ADCY5
SCHEMBL6045717 0.83 ADCY5 (0.75) ADCY5ADORA2AADORA1ADORA2BPI4KA
SCHEMBL6045556 0.83 ADCY5 (0.75) ADCY5ADORA2AADORA1ADORA2BPI4KA
SCHEMBL1565498 0.83 ADORA2A (0.60) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL29728010 0.83 ADORA2A (0.60) EP300ADCY5ADORA2AADORA1ADORA2B
SCHEMBL20158749 0.82 ADORA2A (0.56) EP300ADCY5ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252774-A1 Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF 2006-11-09 US disclosed
US-6887880-B2 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-05-03 US disclosed
US-20020068745-A1 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068745-A1 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof CD38, ADCY1, ADCY2 EP300 2683/4885ADCY5 4/4885ADORA2A 38/4885
US-20060252774-A1 Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases ADCY5, ADCY6, ADCY2 EP300 1519/4885ADCY5 1/4885ADORA2A 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.